Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session

96O - Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial


25 Mar 2021


Proffered Paper session


Tumour Site

Non-Small Cell Lung Cancer


Caicun Zhou


Journal of Thoracic Oncology (2021) 16 (suppl_4): S748-S802.


C. Zhou1, S. Ren2, J. Chen3, X. Xu4, Y. Cheng5, G. Chen6, Y. Pan7, Y. Fang8, Q. Wang9, Y. Huang10, W. Yao11, R. Wang12, X. Li13, W. Zhang14, Y. Zhang15, S. Hu16, R. Guo17, Z. Yang18, L. Wang18

Author affiliations

  • 1 Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN
  • 2 Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN
  • 3 Hunan Cancer Hospital, Changsha/CN
  • 4 Northern Jiangsu People's Hospital, Yangzhou/CN
  • 5 Jilin Provincial Cancer Hospital, Changchun/CN
  • 6 Harbin Medical University Cancer Hospital, Harbin/CN
  • 7 The First Affiliated Hospital of USTC, Anhui Provincial Hospital, 230000 - Hefei/CN
  • 8 Sir Run Run Shaw Hospital ZheJiang University School Of Medicine, Hangzhou/CN
  • 9 Henan Cancer Hospital, Zhengzhou/CN
  • 10 Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming/CN
  • 11 Sichuan Provincial Cancer Hospital, 610000 - Chengdu/CN
  • 12 Anhui Chest Hospital, Hefei/CN
  • 13 The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN
  • 14 The First Affiliated Hospital of Nanchang University, Nanchang/CN
  • 15 Shaanxi Provincial Cancer Hospital, Xian/CN
  • 16 Hubei Cancer Hospital, Wuhan/CN
  • 17 Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing/CN
  • 18 Jiangsu Hengrui Medicine Co., Ltd., Shanghai/CN


Login to access the resources on OncologyPRO.

Abstract 96O


Cytotoxic agents may potentiate immune-checkpoint inhibitors with immunological effects. Camrelizumab plus pemetrexed and platinum is a current standard of care for Chinese patients (pts) with advanced non-squamous NSCLC and negative EGFR/ALK mutation. Here we evaluated first-line camrelizumab plus chemotherapy (chemo) for pts with squamous NSCLC.


In this double-blind, multicenter, phase III trial, previously untreated pts with histologically or cytologically confirmed stage IIIB-IV squamous NSCLC were randomized 1:1 to receive 4–6 cycles of carboplatin (AUC 5) plus paclitaxel (175 mg/m²) with camrelizumab (200 mg) or placebo every 3 weeks, followed by maintenance therapy with camrelizumab or placebo. The primary endpoint was PFS per IRC. Cross-over after disease progression was allowed for pts allocated placebo plus chemo


Totally, 389 pts (camrelizumab plus chemo, n = 193; placebo plus chemo, n = 196) were included. As of Nov. 06, 2020, pts treated with camrelizumab plus chemo were associated with significantly prolonged IRC-assessed PFS versus placebo plus chemo (median, 8.5 [95% CI 6.9–10.4] vs 4.9 [95% CI 4.2–5.5] months; HR, 0.37 [95% CI 0.29–0.47], one-sided P < 0.0001), with benefit observed in pts with both PD-L1 TPS <1% (HR, 0.49 [95% CI 0.35–0.68]) and ≥1% (HR, 0.34 [95% CI 0.24–0.49]). There was also significant improvement in OS for the camrelizumab plus chemo group (median, NR [18.4–NR] vs 14.5 [95% CI 13.2–16.6] months; HR, 0.55 [95% CI 0.40–0.75], one-sided P < 0.0001). Consistently, confirmed ORR (64.8% [95% CI 57.6%–71.5%] vs 36.7% [95% CI 30.0%–43.9%], P < 0.0001) and DoR (median, 13.1 [95% CI 9.3–15.7] vs 4.4 [95% CI 4.2–4.9] months) per IRC favored the camrelizumab plus chemo group. Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.


The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC.

Clinical trial identification


Legal entity responsible for the study

Jiangsu Hengrui Medicine Co., Ltd.


Jiangsu Hengrui Medicine Co., Ltd.


C. Zhou: Honoraria (self): Roche; Honoraria (self): Lily China; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Merck; Honoraria (self), Advisory/Consultancy: Hengrui; Honoraria (self), Advisory/Consultancy: Qilu; Honoraria (self): Sanofi; Honoraria (self): Merck Sharp & Dohme; Honoraria (self), Advisory/Consultancy: Innovent Biologics; Honoraria (self): C-Stone; Honoraria (self): Luye Pharma; Honoraria (self), Advisory/Consultancy: TopAlliance Biosciences; Honoraria (self): Amoy Diagnositics. Z. Yang: Full/Part-time employment: Jiangsu Hengrui Medicine. L. Wang: Full/Part-time employment: Jiangsu Hengrui Medicine. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.